M&A / Deals Beren pockets $300m to take Niemann-Pick disease therapy to market Pharmaceutical TechnologyIf approved, Beren's adrabetadex would join Zevra Therapeutics' Miplyffa and IntraBio's Aqneursa on the I-NPC market.Rare DiseaseRead full story pharminent June 11, 2026 (Last updated: June 15, 2026) Pharmaceutical Technology If approved, Beren’s adrabetadex would join Zevra Therapeutics’ Miplyffa and IntraBio’s Aqneursa on the I-NPC market. Rare Disease Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Aquipta recommended by NICE for acute migraine treatmentNext: Takeda’s $4B TYK2 drug tops Bristol Myers’ Sotyktu in head-to-head test Related Stories M&A / Deals J&J ventures further into in vivo CAR-T space with Sail partnership, potential buyout pharminent July 31, 2026 M&A / Deals Eisai and CORE Biomedicine agree on global licence for oncology pipeline pharminent July 29, 2026 M&A / Deals Argenx signs agreement to buy Forte Biosciences for $2.2bn pharminent July 28, 2026
